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Abstract  
Gastrointestinal dysfunction, often presenting as diarrhoea, is one of the major causes of 
morbidity and mortality among children in low-income countries. It is estimated that 56% of 
child deaths were attributable to malnutrition's potentiating effects in children living in low-
income countries. There are numerous gastrointestinal problems in children in low-income 
countries, in particularly in human immunodeficiency virus (HIV) infected children. The 
gastrointestinal tract is the largest immunological site of the body and HIV infection 
profoundly impacts on gut function and disease development. Most studies of the 
gastrointestinal function in patients in low-income countries have been performed among 
adults. 
The objectives of this thesis are: 1) to examine the prevalence of H. pylori in apparently 
healthy urban Ugandan children and in HIV-infected, highly active anti-retroviral therapy 
(HAART) naïve children in the same geographical area, and 2) to examine if a faecal 
marker for gut inflammation, faecal calprotectin, can be used in children in a low-income 
country living in poor sanitary conditions, and if the marker can be used in an HIV-infected 
population.  
Two surveys were conducted in urban Kampala, Uganda. The first was community-based, 
in children aged 0-12 years, and conducted by door-to-door visits in a neighbourhood 
characterised by slum-like living conditions. The second survey was hospital-based at the 
Department of Paediatrics and Child Health, Mulago National Referral Hospital, Kampala 
where all HIV-infected, HAART naïve children admitted were invited to participate. A 
questionnaire was used in both surveys to address questions about medical conditions and 
socio-economic factors. Faeces were examined for H. pylori by using a rapid monoclonal 
antigen test. Faecal calprotectin was analysed using the ELISA technique.  
The overall prevalence of H. pylori antigen in apparently healthy urban Ugandan children 
aged 0-12 years was 44.3%. Early colonization was common with 28.7% in children 
younger than 1 year of age. There was a steady increase with age (1<3 years 46.0%, 3<6 
years 51.7%, and 6<9 years 54.8%). Children living in permanent houses had a significantly 
lower colonization rate (38.5%) compared to those living in semi-permanent houses, 48.6%. 
HIV-infected children had a lower overall prevalence (22.5%). Age specific prevalence’s 
were; 14.7% in infants 0<1 year, 30.9% among toddles 1<3 years, and 20.7% for children 
3<12 years. HIV-infected children more seriously affected by their disease (lower CD4 cell 
percentage or WHO clinical stage II-IV) were less likely to be colonized with H. pylori. 
Median faecal calprotectin concentrations in apparently healthy Ugandan children were 
comparable to those found in children living in high-income countries. They were 
249mg/kg in infants 0<1 year (n=54), 75mg/kg among toddlers 1<4 years (n=89), and 
28mg/kg for children 4<12 years (n=159). There was no significant difference in faecal 
calprotectin concentration when considering the education of female caretaker, wealth 
index, gender, habits of using mosquito nets, being colonized with H. pylori or having other 
pathogens in the stool. In the HIV-infected children, median faecal calprotectin 
concentrations were different from those in apparently healthy children. They were 
208mg/kg in infants 0<1 year, 171mg/kg among toddlers 1<4 years, and 62mg/kg for 
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children 4<12 years. HIV-infected children more seriously affected by their disease (lower 
CD4 cell percentage) or diarrhoea at enrolment had a higher median faecal calprotectin 
concentration.  
In conclusion, H. pylori colonization among apparently healthy urban Ugandan children is 
common at an early age and increases with age. The prevalence among HIV-infected 
children in the same geographical area is only about half. Faecal calprotectin is also a 
marker for gut inflammation that is well suited for use also in children in low-income 
countries, with the same cut-off values as suggested for children living in high-income 
countries. Faecal calprotectin can also be used as a tool also in an HIV-infected population 
for evaluation of gut inflammation. We found calprotectin to be higher in those HIV-
infected children with more advanced disease, regardless of age.  
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14
Résumé in Norwegian  
Gastrointestinal dysfunksjon, ofte presentert som diaré, er en av hovedårsakene til 
sykelighet og dødelighet blant barn i lavinntektsland. I en rapport fra Verdens 
Helseorganisasjon (WHO) fra 1995 er det anslått at feil-og underernæring er den 
underliggende årsaken til 56% av dødsfallene blant småbarn som lever i lavinntektsland. 
Disse funnene har senere blitt bekreftet. Mage-tarm kanalen er det største immunologiske 
organet i kroppen og humant immunsvikt virus (HIV) påvirker tarmfunksjonen. Det er 
mange gastrointestinale problemer hos barn i lavinntektsland, særlig hos HIV-positive barn. 
De fleste studier av gastrointestinal funksjon hos pasienter i lavinntektsland er blitt utført 
blant voksne. 
Denne avhandlingen har to hovedmål: 1) å undersøke forekomsten av H. pylori hos 
tilsynelatende friske urbane ugandiske barn og hos HIV-smittede, highly active anti-
retroviral therapy (HAART) naive barn i samme geografiske område, og 2) å undersøke om 
en fekal markør for tarm inflammasjon, fekalt kalprotektin, kan brukes hos barn i 
lavinntekts land som lever under dårlige sanitære forhold og om markøren kan brukes i en 
HIV-smittet populasjon. 
For å kunne svare på disse spørsmålene, ble to studier gjennomført i urbane Kampala, 
Uganda. Den første studien ble gjennomført hos 0-12 år gamle barn i oktober / november 
2007 ved dør-til-dør besøk i et nabolag preget av slumlignende levekår. Et spørreskjema ble 
brukt for å belyse spørsmål rundt medisinske forhold og sosio-økonomiske faktorer. 
Avføring ble undersøkt for H. pylori ved hjelp av en monoklonal antigen test. Fekalt 
kalprotektin ble analysert med ELISA teknikk. Den andre studien ble gjennomført mellom 
februar og oktober 2008 ved Barneavdelingen på Mulago National Referral Hospital i 
Kampala. Alle HIV-smittede, HAART naive barn som ble innlagt i denne perioden ble 
inviteres til å delta i studien. Et lignende spørreskjema som i den første studien og de 
samme metoder for påvisning av H. pylori og fekalt kalprotektin ble brukt. 
Den generelle forekomsten av H. pylori antigen i tilsynelatende friske urbane ugandiske 
barn i alderen 0-12 år var 44,3%. Det var en signifikant økning med alder. Tidlig 
kolonisering var vanlig med en forekomst på 28,7% hos barn yngre enn 1 år. Barn som 
levde i permanente hus hadde en betydelig lavere kolonisering, 38,5%, enn de som bodde i 
semi-permanente hus, 48,6%. HIV smittede barn hadde en lavere generelle forekomst, 
22,5%. Blant de HIV smittede barna var den høyeste forekomsten av H. pylori hos barn 
mellom 1-3 år. De eldste barna hadde en forekomst sammenliknbar med forekomsten hos de 
HIV smittede spedbarna. HIV-smittede barn med mer alvorlig sykdom (lavere prosent CD4- 
celler eller WHO klinisk stadium II-IV) hadde mindre sannsynlighet for å være kolonisert 
med H. pylori. 
Konsentrasjonen av fekalt kalprotektin hos tilsynelatende friske ugandiske barn var 
sammenlignbar med nivåene som finnes hos friske barn i høyinntektsland. I de ulike 
aldersgruppene var median fekal kalprotektin konsentrasjon 249mg/kg hos barn 0<1 år 
(n=54), 75mg/kg hos barn 1<4 år (n = 89) og 28mg/kg hos barn 4<12 år (n = 159). Det var 
ingen signifikant forskjell i fekalt kalprotektin konsentrasjon og utdanning av kvinnelige 
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foresatt, familiens økonomiske situasjon, kjønn, vaner med å bruke myggnett, å være 
kolonisert med H. pylori, eller å ha påvist andre patogener i avføringen. Hos HIV-smittede 
barn var nivået av fekalt kalprotektin forskjellig fra det i tilsynelatende friske barn. Median 
fekalt kalprotectin konsentrasjon var 208 mg / kg hos barn i alderen 0< 1 år, 171mg/kg hos 
barn i alderen 1<4 år og 62mg/kg hos barn i alderen 4<12 år. HIV-smittede barn med mer 
alvorlig sykdom (lavere prosent CD4 celler) eller diaré ved innrullering i studien hadde 
høyere median fekalt kalprotektin konsentrasjon uavhengig av alder. 
I denne avhandlingen konkluderes det med at forekomsten av H. pylori hos tilsynelatende 
friske urbane ugandiske barn er høy i en tidlig alder og øker med alderen. Forekomsten 
blant HIV-smittede barn i samme region er tilnærmet halvert sammenlignet med de friske 
barna. Fekalt kalprotektin er en markør for tarm inflammasjon som er godt egnet for bruk 
også hos barn som lever i lavinntektsland, og med samme referanse verdier som foreslått 
hos barn som lever i høyinntektsland. Fekalt kalprotektin kan brukes som et verktøy også i 
den HIV-infiserte populasjonen for evaluering av tarm inflammasjon. I vår studie var fekalt 
kalprotektin høyere hos de med mer avansert sykdom.
Elin Hestvik 
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1 Introduction 
1.1 Gastrointestinal tract: function and dysfunction 
The gastrointestinal (GI) tract consists of the upper and lower tract divided by the ligament 
of Treitz. The upper tract (mouth, throat, esophagus, stomach, and duodenum) is accessible 
or by endoscopy and an accurate diagnosis can be made. The lower tract (jejunum, ileum, 
colon, and rectum) is partly accessible by rectoscopy and colonoscopy, but the jejunum and 
most of the ileum are not. Diseases in the ileum and the jejunum must be diagnosed by 
markers and other modalities, such as ultrasound, computer tomography (CT) or magnetic 
resonance imaging (MRI). Children need general anaesthesia when endoscopy is required. 
In low-income countries including Uganda, endoscopy, CT, and MRI are rarely available 
and diagnosis of the GI tract must be made using other diagnostic tools.  
GI symptoms are common in children all over the world. Different studies report that 
recurrent abdominal pain affects as many as 9-19% of school children, enough to interfere 
with normal daily activity [1, 2]. GI dysfunction, often presenting as diarrhoea, is one of the 
major causes of morbidity and mortality among children in low-income countries [3]. GI 
failure in children has an impact on illnesses associated with growth faltering [4], 
micronutrient deficiencies [5, 6], impaired neurodevelopment [7], and increased morbidity 
and mortality from other childhood diseases [8].  
Diarrhoea accounts for 21% of all deaths in children under five years of age and causes 1.5-
2.5 million deaths per year [9, 10]. Diarrhoea is categorised by the World Health 
Organisation (WHO) as acute and persistent diarrhoea [11]. Diarrhoea is defined as the 
passage of three or more loose or liquid stools per day, persistent diarrhoea lasting for more 
than 14 days. Between 5 and 18% of all diarrhoea episodes in low-income countries become 
persistent [12-14]. Persistent diarrhoea accounts for 50% of all days affected by diarrhoea 
[12]. Malnourished children and those with impaired immunity are more likely to develop 
persistent diarrhoea. Diarrhoea, in turn, tends to worsen their condition. 
H. pylori is considered to be the major cause of recurrent chronic gastritis and duodenal 
ulcer disease in childhood. Some studies also suggest that gastric infection with H. pylori is 
associated with sub-optimal nutrition and retarded growth in childhood [15]. Studies in 
Africa have shown a significant increase in H. pylori prevalence with age [16, 17].  
Faecal calprotectin is a marker for gastrointestinal inflammation and is frequently used to 
distinguish between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) 
[18]. 
The GI tract is the largest immunological site of the body and human immunodeficiency 
virus (HIV) infection profoundly impacts on gut function and disease development [19, 20]. 
There are numerous GI problems in children in low-income countries and in particularly in 
HIV-infected children [20-22]. In low-income countries, it is estimated that diarrhoea may 
occur in as many as 80% of HIV-infected individuals [23].  
Elin Hestvik 
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1.2 HIV in Ugandan children 
1.2.1 Epidemiology 
Sub-Saharan Africa accounts for 67% of all people living with HIV, and carries the highest 
burden of the global HIV epidemic [24]. In Uganda, 940.000 people, including 130.000 
children were living with HIV in 2007 [24]. About 1000 children are infected with HIV 
each day worldwide. At the end of December 2008, only 32% of HIV-infected children less 
than 15 years of age in eastern and southern Africa needing HAART were on therapy 
(http://www.who.int/hiv/topics/paediatric/data/en/index1.html). About 1.2 million children 
are orphaned in Uganda due to HIV/AIDS (http://www.unicef.org/infobycountry/uganda 
_statistics.html).
  
1.2.2 CD4 cell count and clinical staging in HIV-infected children  
Children have a natural decline in CD4 (cluster of differentiation 4) cell count with age [25] 
and therefore it is more correct to report CD4 cell count in children as a percentage of the 
total lymphocyte count. The WHO therapy guideline, available at the time of the study [26], 
recommended starting HAART in children at different levels of CD4 percentage dependent 
on age, table 1. The newest WHO treatment guidelines recommend starting HAART in all 
HIV-infected children younger than two year of age, between 24 and 59 months of age with 
CD4 cell percentage 25, and in children older than 5 years of age with CD4 cell count 
350 cells/mm3 [27]. 
Table 1. CD4 cell criteria for severe HIV immunodeficiency  
Age-specific recommendation to initiate HAART bImmunological 
Marker a
 11 months 12- 35 months 36 - 59 months  5 years 
CD4 cell % c < 25 < 20 < 15 < 15 
CD4 cell count c
(cell/mm3) 
<1500  < 750 < 350 <200 
             (Copied from the WHO guideline [26]) 
a  Immunological markers supplement clinical assessment and should therefore be used in 
 combination with clinical staging. CD4 is preferably measured after stabilization of acute presenting 
 conditions. 
b  HAART should be initiated by these cut-off levels, regardless of clinical stage; a drop of CD4 below 
 these levels significantly increases the risk of disease progression and mortality. 
c  CD4 cell percentage is preferred for children aged <5 years. 
In most settings where HIV treatment is provided today, virological testing and CD4 cell 
count diagnostic are available. Despite this, clinical staging is still an important tool for 
follow up after initiating treatment and also in some cases for treatment initiating. The 
WHO clinical staging system has 4 stages; 1 asymptomatic, 2 mild, 3 advanced, and 4 
severe, for more detail, see appendix VI. All children should be classified according to this 
system, independent of virological testing and CD4 cell diagnostic. Many of the symptoms 
in the clinical staging system are due to opportunistic infections (OI). Children are identified 
as stage 3 when they have symptoms from disease in the GI tract, and regardless of CD4 
cell count, initiating HAART is recommended.  
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1.2.3 Gastrointestinal aspects and HIV enteropathy 
Worldwide, GI disease continues to account for a high proportion of presenting symptoms 
of HIV infection, especially in low-income countries [19, 20, 28-30]. Children with a low 
CD4 cell percentage are more at risk for acute and persistent diarrhoea [31]. Common 
conditions in children living in low-income countries are much more frequent in HIV-
infected children with a much higher mortality and morbidity rate than non-HIV-infected 
children. In a study from Rwanda, the initial clinical sign that occurred most frequently was 
failure to thrive [32]. Children living with HIV without HAART treatment die due to other 
OI  and GI failure [33].  
Studies have shown that invasive investigations, demanding general anaesthesia in children, 
such as colonoscopy with intubation and biopsy of the terminal ileum together with 
endoscopy of the upper GI tract are necessary to identify GI opportunistic infections at high 
rates [29]. Numerous pathogens found in HIV-infected persons with diarrhoea are atypical 
and need highly sophisticated methods to be identified [23]. If identification is done, the 
treatment recommendations for many of the pathogens found are still pending [34] and if 
known, the drugs needed are often not available in low-income countries. Studies have 
shown that initiating HAART is one of the most effective treatment for many of the 
opportunistic infections [23].  
Increased intestinal permeability in HIV-infected populations has been confirmed by several 
studies [35-37], and occurs in 40-60% of children with symptomatic HIV infection [38, 39]. 
This data comes from studies of children in high-income countries. Commonly among these 
studies, they have tested for carbohydrate malabsorption, and it has been concluded that 
there are increased small intestinal permeability. Sharpstone et al. [37] used a lactulose/L-
rhamnose test to show that all AIDS infected participants in the study except from those 
being defined as “well”, had significantly increased intestinal permeability compare to 
healthy controls. Greenson et al. [40] found that adults with AIDS with and without 
diarrhoea have a significantly reduced villius/crypt ratio, villius height ratio and crypt depth 
compared to normal controls. Knox et al. [30] investigated 671 HIV-infected persons, 39% 
had diarrhoea, stool pathogens were identified in only 12% of these patients. Despite this, 
48% of all patients had an abnormal D-xylose test, 22.5% had borderline or low serum B-12 
levels, and 7.2% had a depressed albumin level. Especially the abnormal D-xylose test and 
depressed levels of albumin are pointing to a GI malabsorption in those HIV-infected. 
Increased malabsorption is often associated with increased permeability of the GI tract [37]. 
Gori et al. [41] investigated 53 healthy, asymptomatic, HAART naïve Italian adults and 
found faecal calprotectin to be higher than 50mg/ml in 27 subjects. They concluded that the 
GI tract in HIV-infected patients is impaired in the early phase of the disease, and that this 
impairment is associated with elevated levels of gut inflammatory markers.  
Many factors contribute to GI dysfunction in HIV-infected persons [42]; frequent causes in 
low-income countries are different pathogens [23] or Clostridium difficile after protracted 
antibiotic treatment [42]. After endoscopy with biopsies, there are cases without an 
identified cause of a GI disorder; these are frequently referred to as HIV enteropathy. The 
exact pathogenesis of HIV enteropathy remains unclear, but has been attributed to 
dysegulation of local cytokine production and destruction of gut-associated lymphatic tissue 
(GALT), and HIV replication in residual GALT [43, 44]. It will be a combination of these 
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in most cases. HIV enteropathy can exist in HIV positive patients with refractory diarrhoea 
in a small percentage of the population, but OI must first be excluded [23]. Exclusion of OI 
has limitations as mentioned above. Over the time, since the identification of HIV, more 
pathogens have been identified and fewer changes in the GI tract are currently believed to 
be caused by HIV enteropathy [23].  
1.3 Helicobacter pylori 
1.3.1 Biology and origin 
H. pylori is one of the most common causes of bacterial infection in human beings [45], 
with probably more than 50% of the world population being infected. It was first isolated 
and cultured by Warren and Marshall in 1983 [46], but spiral-shaped or curved bacilli were 
found in the human gastric mucosa already more than 100 years ago [47], with similar 
organisms being seen in the gastric mucosa of mammals as early as 1896 [48]. Initially it 
was termed Campylobacter-like, but was later assigned the name Campylobacter pyloridis
because of its principal localization in the lower pyloric parts of the stomach. The name was 
changed to H. pylori in 1989, when taxonomic features of the bacterium shown that it was a 
genus of its own [49]. The role of H. pylori in duodenal and gastric ulcer disease was 
established and reported in a consensus statement in 1994 [50] as a result of the accelerating 
research on both microbiological aspects and pathogenic role of this newly discovered 
bacteria. In 1994, the International Agency for Research on Cancer (IARC) concluded, after 
numerous epidemiological studies investigating the link between H. pylori,  gastric cancer 
and mucosa- associated lymphoid tissue (MALT)-lymphoma, that H. pylori is carcinogenic 
to humans and thus classified H. pylori as the first bacterial Group I carcinogen [51]. 
H. pylori is a Gram-negative, urease-, catalase- and oxidase positive bacterium that inhabits 
the mucous layer of the gastric mucosa of the stomach. The bacterium is about 3 
micrometers long with a diameter of ~ 0.5 micrometer and has up to 6 sheeted polar flagella 
that are important for its mobility. The characteristic high urease activity is used by the 
bacteria to convert urea in the gastric juice to ammonia and bicarbonate. These products 
buffer the gastric acid and create a friendly microenvironment for H. pylori [52].  
Only a small percentage of colonized individuals will express clinical manifestation. A 
proposed determinant for the outcome of colonization is the ability of the bacterium to 
attach to the gastric epithelium. Electron microscopy has confirmed the presence of the tight 
adherence of H. pylori to the gastric cell surface through formation of membrane attachment 
pedestals similar to those described with the enteropathogenic bacterium, Escherichia coli 
[53, 54]. 
Bacterial attachment is partially mediated by a number of adhesins and outer membrane 
proteins. Three Hop proteins have been implicated in the pathogenesis of H. pylori
infection, BabA, OipA and SabA [55]. BabA mediates binding to fucosylated Lewis b 
(Le(b)) blood group antigens on host cells [56]. OipA may serve as an adhesin but it also 
promotes inflammation by increasing IL-8 expression [57]. SabA mediates binding to 
glycoconjugates containing sialic acid [58].  
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Functional differences exist between strains of H. pylori that may relate to virulence and 
tissue damage [59]. Vacuolating cytotoxin, vacA, is secreted by ~ 50% of H. pylori isolates 
in high-income countries. Infection with vacA positive strains is reported to be associated 
with gastric and duodenal peptic ulcerations, and gastric cancer [60, 61]. VacA behaves as a 
passive urea transporter that is potentially capable of increasing the permeability of the 
gastric epithelium to urea, thereby creating a favourable environment for H. pylori
infectivity [62]. Virulence of VacA appears to depend upon the function of a tyrosine 
phosphatase receptor in gastric epithelial cells [62]. H. pylori  strains with different VacA 
alleles have differing toxicity [63].  
CagA protein is another putative virulence factor, encoded by the cagA gene (cytotoxin 
associated gene A) [64, 65]. This gene is present in ~ 60% of H. pylori isolates [66]. 
Although the function of CagA protein is unknown, the protein seems to be associated with 
peptic ulcer [67] and gastric cancer in Europe and North America [68, 69]. CagA -positive 
H. pylori strains are associated with interleukin-8 (IL-8) induction in gastric epithelium. 
Neutrophilic infiltration into the gastric epithelium, which is characteristic of H. pylori 
infection, may be due to the increased production of IL-8. CagA protein may therefore be 
related to gastric inflammation and gastroduodenal diseases [70]. Strains producing VacA 
and CagA cause more intense tissue inflammation and induce cytokine production [71-73].  
1.3.2 Diagnostic modalities 
The 13Urea breath test [74, 75] or invasive methods, such as gastroscopy with biopsies 
and/or urease tests used to be the “gold standard” for detecting of H. pylori. The 13Urea 
breath test is a very time- and personnel-consuming test, where much collaboration between 
investigator and patient is required. The patient have to stop taking acid-reducing 
medication 14 days in advance of the test, have to fast for 4-6 hours in advance of the test, 
then drink a juice before exhale into a bag often through a straw. This test has been reported 
to be done concurrently in young children and infants, but it is to some extend unsuitable for 
children. For the urease test and for culture of H. pylori a gastroscopy is required. To 
perform gastroscopy in children, general anaesthesia is required, and again this is time- and 
personnel-consuming, and invasive and unsuitable for children. The faecal monoclonal 
antigen test we used has high sensitivity, specificity, and accuracy in children, 91-96%, 95-
96% and 94-96%, respectively [76, 77]. The faecal test can be performed in all age groups 
and gives rapid results without the need for sophisticated laboratory equipment. Acid-
reducing medication can be continued. Common to all the tests mentioned above is the 
measurement of an ongoing H. pylori infection and H. pylori must be present at time of 
investigation.  
Serological tests are also available, but in children they often show very low sensitivity and 
specificity [78-80]. A major drawback of serological tests is that they do not discriminate 
between current and past infections. A specific IgG may remain positive for years after the 
infection has been cleared. The joint European and North American guideline [81] does not 
recommend using serology in a clinical setting for children. 
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1.3.3 Epidemiology 
H. pylori colonization is acquired early in life. The mode of transmission of H. pylori is not 
fully understood, and no certain environmental source has been identified [82]. In fact, it 
has been proposed that humans are the only reservoir of H. pylori [83]. Different routs of 
transmission are suggested, faecal–oral and oral-oral. Early colonization in children living 
in poor socio-economic conditions has been demonstrated, and several studies have shown a 
high prevalence of H. pylori among people in low-income countries [16, 84-86]. There is a 
substantial gap in prevalence in low- and high-income countries. In low-income countries, 
the prevalence of H. pylori infections often reaches 50% among 5-years old children, 
whereas in high-income countries the prevalence is low (<10%), table 2 and 3.  
Table 2. Prevalence of H. pylori among asymptomatic children in sub-Saharan Africa 
Population Author Comment a Age (years) Number b % H. pylori + 
Ethiopia Lindkvist [87] Serology 2-4 248 48 
South-
Africa 
Pelser [84] Serology <2 
2-5 
5-10 
104 
103 
104 
13.5 
48.5 
84.2 
Kenya Langat [86] Stool 
antigen 
0-3 195 45.6 
Tanzania Mbulaiteye 
[88] 
Serology 0-4 
5-9 
10-17 
181 
180 
152 
76 
93 
97 
Cameron  Ndip[16] Stool 
antigen 
0<3 
3-6 
7-10 
32 
106 
38 
37.5 
50.0 
71.1 
Nigeria Holcombe 
[89] 
Serology <10 
10-19 
100 
43 
69 
91 
Gambia Sullivan [90] Serology 1.5-3.3 
3.5-5 
136 
135 
27 
46 
a Test method uses to identify H. pylori colonization 
b Number of participants in the study 
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Table 3. Prevalence of H. pylori among asymptomatic children in other parts of the world 
Population Author Comment a Age (years) Number b % H. pylori + 
Norway Stray-
Pedersen 
[91] 
Stool 
antigen 
0-7 days 
7-30 days 
1month-3 y 
69 
46 
134 
52 
15 
  5 
Sweden  Granstrom 
[92] 
Serology 2  
4 
11 
237 
185 
201 
10.1 
7.5 
3.0 
Germany Grimm [93] 
Rotenbacher 
[94] 
13Urea 
breath 
Serology 
7-20 
6 
540 
475 
9.4 
5 
Turkey  Abasiyanik 
[95] 
Serology 1-9 
10-19 
33 
56 
42 
55 
Tunisia K. Siai [96] Serology 6-7 1055 51.4 
Brazil Kawakami 
[97] 
13Urea 
breath 
0-1 
2-5 
6-10 
11-20 
86 
273 
313 
529 
12.8 
19.4 
28.8 
46.3 
Canada c Segal [98] 13Urea 
breath 
5-18 214 7.1 
Hong Kong d Tam [99] 13Urea 
breath 
6-19 2480 13.1 
India Mishra [100] Nested 
PCR 
in faeces 
0-5 
6-10 
11-16 
47 
22 
68 
4.3 
13.6 
50.0 
a  Test method uses to identify H. pylori colonization 
b  Number of participants in the study 
c  Referred for upper endoscopy  
d  Chinese children residents in Hong Kong  
1.3.4 Helicobacter pylori and HIV 
There is little data on the prevalence in HIV-infected children, both in high- and low-
income countries, table 4. To the best of our knowledge there is only one study from sub-
Saharan Africa reporting the prevalence of H. pylori in HIV-infected children, and there are 
no studies performed in child populations showing differences in the prevalence of H. pylori 
according to CD4 cell count. The study, reporting the prevalence of H. pylori in HIV-
infected African children, was designed to describe the findings in HIV-infected South-
African children who underwent gastroscopy. They also reported the rates of H. pylori 
colonization, with only one out of 26 children was colonized [101]. Only two studies were 
done with the aim of assessing the prevalence of H. pylori in HIV-infected children [102, 
103], none of them from endemic areas for HIV. A Belgian study [102] on 23 HIV-infected 
children of Central African origin, born in Belgium used a serology test to detect H. pylori 
colonization. They found none of the tested children to be colonized compared to 19.2% in 
a control population. An Italian study [103], using serology and 13Urea breath tests in 45 
perinatally HIV-infected children found prevalences of 17.7 and 20% respectively. In a 
review on the incidence of H. pylori in HIV-infected adults [104], diverging estimates of the 
prevalence of H. pylori were found. In a study from Argentina on adults [105], the authors 
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concluded that HIV-infected patients with H. pylori had a higher mean CD4 cell count than 
those without H. pylori, and a Zambian study [106] showed that HIV-infected adult patients 
with CD4 cell counts below 200cells/mm3 were less likely to have positive H.  pylori
serology (odds ratio [OR] 0.29 [95% CI 0.09–0.93]). Many studies from sub-Saharan Africa 
have used serological tests [107-109], which have been shown to have a lower specificity in 
children.   
Table 4. Prevalence of H. pylori among HIV-infected children 
Population Author Diagnostic 
method(s) 
Age 
(years) 
Number c % H. pylori + 
South Africa Cooke [101] Endoscopy  0-12 26 3.8 
Belgium a Blecker [102] Serology 1-15 23 0 
Italy  Lionetti [103] Serology + 
13Urea breath b
1-13 45  17.7 
20.0 
a Central African origin 
b  Serology and 13Urea breath test were performed in all children 
c Number of participants in the study 
1.3.5 Clinical aspects 
H. pylori is probably the major cause of recurrent chronic gastritis and duodenal ulcer 
disease in childhood. However, the association between H. pylori and recurrent abdominal 
pain (RAP) syndrome is still controversial. Until now, no association has been found 
between RAP and H. pylori infection [110]. A French group could not find any specific 
characteristics of symptoms in H. pylori infected children that had non-peptic dyspepsia 
[111]. Peptic ulcer disease is not particularly common among children, but is often caused 
by H. pylori [112]. Some studies also suggest that  gastric infection with H. pylori is 
associated with sub-optimal nutrition and growth in childhood [15]. H. pylori  has also been 
linked to iron deficiency anaemia [113, 114].  
The connections between H. pylori infection and auto-immune thyroid disorder [115], and 
H. pylori infection and respiratory infection/acute otitis media [116], have been evaluated, 
but no significant association has been found. Furthermore, H. pylori infection is associated 
with cancer, but this is not often seen in children due to the long delay in developing the 
disease. H. pylori infections are associated with gastric cancer, MALT lymphoma and colon 
cancer, but the last one remains controversial. 
1.3.6 Treatment of Helicobacter pylori in children 
The first consensus report on treatment of H. pylori in European children [117] was 
published in 2002. The Canadian Helicobacter Study Group updated the Canadian 
consensus in 2005 [118]. Recently a joint evidence-based guideline [81] from the European 
Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the 
North American Society of Pediatric Gastroenterology, Hepatology and Nutrition 
(NASPGHAN) has been published. It aims to answer 4 questions: 1) Who should be tested? 
2) What test should be used? 3) Who should be treated? and 4) What treatment regiments 
are most appropriate?. The guidelines stress that they only applies to children living in 
Europe and North America, and particularly not for low-income countries. There is no 
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general consensus on the treatment of children or for treating H. pylori in low-income 
countries with a high prevalence in children. A general treatment for all infected humans is 
not recommended. Only in H. pylori positive children with symptoms or GI ulcers 
demonstrated, is a tipple therapy is recommended.  The combinations recommended in the 
joint guideline are a proton pump inhibitor (PPI) +Amoxicillin + Imidazole or 
Clarithromycin; alternatively Bismuth salts + Amoxicillin + Imidazole [81]. 
1.4 Faecal calprotectin 
1.4.1 Biochemistry and origin of calprotectin 
Calprotectin was discovered in 1979 by Fagerhol et al. [119] while searching for a simple 
assay for granulocyte turnover in vivo. Calprotectin is a calcium and zinc binding 
heterocomplex protein consisting of two heavy chains and one light one. It belongs to the S-
100 protein family. The protein constitutes ~ 60% of the soluble proteins in the cytosol 
fraction of neutrophils [120]. In the early literature, it is also called MRP8/14 and L1 
protein. Calprotectin has not been detected in B or T lymphocytes, erythrocytes, platelets or 
any non-myeloid cells of the intestines or pancreas [121, 122]. The protein is distributed in 
myelomonocytes, such as neutrophil granulocytes, monocytes and activated macrophages, 
and in submucosal epithelial cells [121, 122]. It is a putative protective protein that is 
remarkably resistant to degradation in vivo and in vitro in the presence of calcium, so faecal 
samples can be sent to the laboratory by mail. It is stable in faeces stored for 7 days at 
ambient temperature [123]. Calprotectin and its subunits appear to have regulatory functions 
in the inflammatory process, and various biological functions including antimicrobial and 
antiproliferative activity have been ascribed to the protein. 
1.4.2 Faecal calprotectin analysis 
A faecal calprotectin ELISA test has been available since 1994 [124].  Fagerberg et al. [125] 
have established a reference value for healthy Swedish children aged 4-17 years using an 
improved assay (Calprest®, Eurospital, Trieste, Italy) with greater sensitivity than 
previously available. Her conclusion was that the suggested cut-off level in adults, <50µg/g, 
can be used for children aged 4-17 years regardless of sex. In young infants, high faecal 
calprotectin concentrations are normal [126, 127]. In healthy pre-term babies the 
concentrations are comparable with those in healthy term babies [128, 129]. Studies diverge 
in their conclusions as to weather faecal calprotectin is higher in exclusively breast-feed 
children than in mix feed children [130, 131]. Faecal calprotectin decrease with age and in 
healthy children reaches stabile low levels as found by Fagerberg et al. at about 4 years of 
age.  
1.4.3 Calprotectin in body fluids 
Calprotectin is a normal constituent of human plasma. Normal levels of calprotectin in 
plasma are between 90 and 530µg/l in women and between 120 and 660µg/l in men [132]. 
Levels in plasma/serum increase in response to different types of inflammation or damage 
of tissue. Calprotectin is found in saliva and levels are different in parotid saliva and whole 
saliva [133]. The protein is found in cerebrospinal fluid in trace amounts [120]. High levels 
of calprotectin are found in synovial fluid in patients with rheumatoid arthritis, plasma 
levels reflecting disease activity [134]. 
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1.4.4 Faecal calprotectin and gastrointestinal disease  
Increased faecal calprotectin is a marker for increased permeability of the GI tract [124]. In 
very low birth weight babies (VLBW) developing severe abdominal disease, for instance 
necrotizing enterocolitis (NEC), faecal calprotectin concentrations tend to increase more 
than in VLBW babies without NEC, and it may be a marker for early diagnosis [128, 129]. 
Faecal calprotectin levels are elevated in adults [123, 135] and children [126, 136, 137] with 
inflammatory bowel disease (IBD) and might be used to evaluate the degree of 
inflammation in these patients. Faecal calprotectin is used in paediatric clinics today as a 
“screening” for IBD in children transferred with recurrent abdominal pain or 
recurrent/prolonged diarrhoea. Faecal calprotectin may differentiate between functional 
abdominal pain and IBD in school-age children [138]. A significant correlation is found 
between calprotectin concentration in gut lavage fluid and intestinal permeability, 
suggesting that increased intestinal permeability in IBD might be a consequence of 
increased transepithelial migration of neutrophils [139]. Faecal calprotectin is also elevated 
in patients with GI cancer [140] and NSAID induced enteropathy [141]. In diagnosed 
colorectal cancer, faecal calprotectin concentrations above an upper reference limit were 
found in more than 90% of the patients in a Norwegian study [123]. Lymphonodular 
hyperplasia in the gut is common in infants and young children [142, 143], it occurs 
frequently in children with food protein-induced colitis [144], disrupts the normal mucosa 
[142], and increased levels of faecal calprotectin can occur. Faecal calprotectin 
concentrations have also been analysed in children with acute gastroenteritis [145, 146]. The 
concentration is elevated when compared to healthy children, but not as high as in IBD. In 
an Italian study of children aged 1-18 years, referred for gastrointestinal symptoms, faecal 
calprotectin was higher in those with acute gastroenteritis, but these children had a 
considerably lower mean age than 4 years [146]. In a study of 46 children, with bacterial GI 
infections, faecal calprotectin was not elevated regardless of the pathogen compared to 23 
healthy controls [147]. It is known that the permeability of the gastrointestinal tract can be 
increased by gastroenteritis. This can lead to a higher concentration of faecal calprotectin 
due to higher levels of granulocytes in the lumen. Faecal calprotectin is a sensitive, but not 
disease-specific marker useful in detecting inflammation throughout the whole 
gastrointestinal tract in children. 
1.4.5 Calprotectin and HIV/AIDS 
To the best of our knowledge, there are no published articles on faecal calprotectin in 
children living with HIV/AIDS, except the work presented in this thesis. In 53 HIV-
infected, HAART naïve Italian adults, faecal calprotectin has been found elevated in half of 
the patient [41]. Patients with HIV developing oral candidiasis, had significantly lower 
parotid calprotectin levels than those who did not [148-150].  Significantly elevated levels 
of calprotectin were found in the serum of 51 HIV-positive patients, both in asymptomatic 
patients and patients who had developed AIDS, compared with controls. The calprotectin 
level was not related to ongoing or recent opportunistic infection [151]. Calprotectin levels 
in cerebrospinal fluid have been studied in patient with HIV who developed symptoms of 
the CNS. Patients with opportunistic CNS-infections had levels above the reference limit, 
and patients with HIV-associated encephalopathy had levels within the reference range 
[152], but the sample size was low (15 patients).  
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2 Aim and objectives 
2.1 Overall aim 
The overall aim of this thesis was to assess the prevalence of H. pylori in Ugandan children, 
and to explore whether faecal calprotectin can be used in the clinical management of HIV in 
Ugandan children.  
2.2 Specific objectives 
The specific objectives were to:  
a) Assess the prevalence and associated factors with H. pylori in apparently healthy children 
aged 0-12 years in Kampala, Uganda (Paper I). 
b) Assess the prevalence and associated factors with H. pylori in HIV-infected, HAART 
naïve children aged 0-12 years in Kampala, Uganda (Paper II).  
c) Establish reference values for faecal calprotectin concentrations in apparently healthy 
children aged 0-12 years in Kampala, Uganda (Paper III). 
d) Determine faecal calprotectin concentrations in HIV-infected, HAART naïve children 
aged 0-12 years in Kampala, Uganda (Paper IV). 
e)  Study the correlation between the concentrations of faecal calprotectin and CD4 cell 
percentage in HIV-infected, HAART naïve children aged 0-12 years in Kampala, Uganda 
(Paper IV). 
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3 Methods 
3.1 Study area and population 
Uganda is a landlocked country in East-Africa; its neighbouring countries are Kenya, 
Sudan, Democratic Republic of the Congo, Rwanda and Tanzania, figure 1. Approximately 
50% of the population is living below the international poverty line of US $ 1.25 per day, 
and the gross domestic product (GDP) per capita is ~ US $ 500. In 2008, the population of 
Uganda was estimated at 30 million people of whom ~ 1.5 million live in the capital city 
Kampala (www.ubos.org). Kampala has five divisions, one of them being Kawempe, figure 
2. Kawempe division houses 22% of Kampala’s population. Both surveys were carried out 
in Kawempe division.  
Figure 1. Uganda with bordering countries             Figure 2. The 5 divisions of 
Kampala: Kawempe, Rubaga, 
Central, Nakawa and Makindye. 
The community-based survey was 
carried out in Kawempe   
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3.2 Design, sampling and data collection 
 
The data in this thesis are based on two surveys conducted in 2007 and 2008; 
 1. Apparently healthy children 
 2. HIV-infected, HAART naïve children 
 
Table 5. Connections between the two study populations and the test used inn all 4 papers 
 
Two populations 
Two tests 
Apparently healthy 
Ugandan children 
HIV-infected 
Ugandan children 
Helicobacter pylori 
-faecal monoclonal antigen test 
Paper I Paper III 
Faecal calprotectin 
-ELISA 
Paper II Paper IV 
 
 
Both surveys were conducted in Kampala, Uganda. Both surveys included children aged 0-
12 years, figure 3.  
 
 
 
Figure 3. Enrolment and study profiles of both surveys 
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3.2.1 Apparently healthy children 
A cross-sectional survey was conducted by door-to-door visits in October and November 
2007. The study was carried out in all zones of Mulago II parish, one of the 22 parishes of 
Kawempe division, and one of 5 divisions in Kampala. The data collection was done within 
six weeks by eight data collectors. Elin Hestvik accompanied the data collectors in the field 
daily.  
        (Picture from www.maps.google.com)
Figure 4. Settlement of the Kawempe division  
3.2.2 HIV-infected, HAART naïve children 
This was a hospital-based survey. The hospital is situated within the Kawempe division and 
it is owned and run by the Ugandan government. It is the district hospital for people living 
in the area of Mulago Hill at Kawempe division, at the same time being the national referral 
hospital for the whole of Uganda. Participants were enrolled from the general paediatric 
medical wards, the acute care unit, the ward for malnutrition and the paediatric infectious 
diseases clinic (PIDC) at Department of Paediatrics, Mulago National Referral Hospital, 
Kampala between February and October 2008. The daily enrolment and investigations of 
participants were done by an Ugandan medical doctor employed for the project. The data 
collection was monitored by Dr. Grace Ndeezi on site and Elin Hestvik. For HIV-infected 
children the enrolment period was set at 9 months prior to the study, according to 
experience in the paediatric clinic and the number of children who had been newly 
diagnosed with HIV monthly. We had to accept a low number of HIV-infected, HAART 
naïve older children due to the natural history of HIV.  
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Figure 5. A general paediatric medical ward at Department of Paediatrics, Mulago National 
Referral Hospital, Kampala. 
3.3 Statistical procedures 
3.3.1 Sample size 
OpenEpi (www.openepi.com) was used to calculate the sample sizes based on assessing a 
single proportion with a narrow confidence interval. In the survey of apparently healthy 
children we assumed a 50% prevalence of H. pylori colonization in the apparently healthy 
children, and in the HIV-infected children we assumed 30%. A 95% CI was used for the 
estimates. The sample sizes were calculated with the formula:  
n = [DEFF*Np(1-p)]/ [(d2/Z21-/2*(N-1)+p*(1-p)].  
DEFF= design effect=1 (we did not had to adjust for cluster sampling) 
N= total population size is large, assumed to 1million  
p= prevalence, assumed prevalence of H. pylori was 50%  
d= confidence limits (absolute precision) fixed to 5% 
= 0.05 by a CI 95% as we used 
Z = Z value (e.g. 1.96 for 95% confidence level)   
This gave us a sample size of 384 apparently healthy children and 323 HIV-infected 
children. Another 10% was added to allow for contingency in the survey of apparently 
healthy children, a total of 422. 
3.3.2 Statistical procedures and data management 
Data from the questionnaires and biochemistry were doubly entered using EpiData version 
3.1 (www.epidata.dk). The data were exported to SPSS version 15.0 for paper I and version 
17.0 for paper II-IV for statistical analysis. Data quality was ensured through careful 
selection and training of research assistants, supervision, field editing by use of the “check” 
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module at data entry, and double data entry and validation. The “checks” at data entry were 
limits set by the study team to ensure that it was impossible to enter clearly inaccurate 
information. A child could only be between 48 and 180 cm; it is impossible to enter other 
data and many answers could only be “yes” or “no”. After entering all data twice in separate 
files, the 2 separate data files were validated by comparison and any non-matching data 
were checked manually against the original paper form. 
To assess the prevalence of H. pylori and its association with other factors in paper I and III, 
binary logistic regression as well as multiple logistic regressions were performed. Findings 
are presented in odds ratios with their confidence intervals (CI).  
In paper II and IV, faecal calprotectin concentrations were expected to have a skewed 
distribution; the median was used. Faecal calprotectin values in the different groups were 
compared by using the Mann-Whitney U test (for two different groups) and by the Kruskal-
Wallis H test (for three or more groups). To control for diarrhoea as a confounder for a low 
CD4 cell percentage in the HIV-positive group, linear regression was used.  
The confidence interval reported was set to 95%. All tests were 2-sided, p-value of 0.05 or 
less was considered significant. Age was reported in mean and years with standard deviation 
(SD). Principal component analysis was used, to explore the socio-economic status of the 
participants. 
In paper III and IV CD4 cell percentage was classified as high or low with limits defined by 
age: 1) for children <12 months high if CD4 cell > 25%, 2) for 12<36 months high if CD4 
cell > 20% and 3) for 36 months high if CD4 cell >15%. The limits chosen were consistent 
with the limits recommended for starting HAART according to the WHO guidelines 
available at the time of the study [26]. All children were clinically categorized using the 
WHO staging system [153] for HIV-infected children. For further details on the WHO 
staging see Appendix VI.  
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3.4 Helicobacter pylori antigen test 
For the detection of H. pylori in both surveys, an antigen test called  
ImmunoCard STAT!HpSA was used. It is a rapid 5 minutes immunoassay based on a lateral 
flow chromatography technique using a monoclonal antibody for the qualitative detection of 
H. pylori antigens in human stool. Unlike serological tests, the detection of H. pylori 
antigens in the stool identify a current (= ongoing) infection using a truly non-invasive 
method. It can be used for diagnosing the infection, as well as for confirming eradication 
four weeks after the end of the therapy.  
For both surveys, the stool specimen was collected in empty air-tight container and was 
stored in the fridge until the same afternoon or next morning before testing. 
The manufacturer instructions were followed; the applicator stick of the diluent vial was 
used to transfer a small portion (5-6 mm in diameter) of stool specimen into the sample 
diluents, which was vortexed for 15 seconds. The tip of the vial was broken off, and four 
drops were dispensed into the round window at the lower end of the device before reading 
the result after five minutes. The results were interpreted as followed:  
Negative: one BLUE line (control) 
Positive: one BLUE line (control) and one PINK-RED line (test). 
After every 20 tests, a positive control was run.  
                                                                                  Copied from www.mdeur.com
Figure 6.  Rapid method for H. pylori antigen detection      
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3.5 Faecal calprotectin measured by ELISA technique
For measuring faecal calprotectin concentrations in both surveys, we used the 
CALPROCalprotectin ELISA Test (ALP), a quantitative method for the determination of 
calprotectin in stool samples.  
After taking stool from the air tight container for H. pylori, microscopy and culture, faeces 
were frozen within 48 hour after collection in Eppendorf tubes, taking ~ five gram at -80°C. 
At the end of both surveys, the faeces were transported frozen to Bergen, Norway on ice for 
the analysis, which was done in July 2008 (for apparently healthy children) and august 2010 
(for HIV-infected children).   
We followed the manufacturer instructions. Faeces were defrosted at room temperature, 
~100 mg were placed in a screw-cap tube and diluted at the ratio1:50 with extraction buffer. 
The solution was vortexed for 30 minutes. 1-2 ml of the homogenate was transferred to an 
Eppendorf tube and centrifuged at 10.000g for 20 minutes. About 0.5 ml of the clear 
supernatant was transferred to a new tube and stored at +4°C until the next day. The extracts 
were diluted 1:50 before running. 50 l of the 8 standards, the controls and the diluted 
samples were added to the ELISA plate (96 wells). The plate was covered with a sealing foil 
and incubated at room temperature for 45 minutes. It was washed 5 times and 50 l of the 
conjugate was added to each well. The plate was again sealed and washed. 100 l substrate 
solution was added to each well and thereafter incubated at room temperature for 20-30 
minutes. 100 l stop solution was added to each well. The optical density values were read 
by the means of an ELISA reader at 405 nm. The values of the diluted samples were 
corrected for the dilutions and converted to mg/kg by multiplying by 2.5.  
  
                                          Copied from www.phical.com
Figure 7. ELISA techniques for determination of faecal calprotectin levels
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3.6 Ethical considerations 
The research protocols for the apparently healthy children and the HIV-infected children 
were approved by the Regional Committee for Medical and Health Research Ethics, West-
Norway (REK-VEST) in Norway and Makerere University, Faculty of Medicine, Research 
and Ethics Committee in Uganda. Oral and written information about the study was given to 
the caretakers either in English or the local language. Informed consent was obtained from 
all the caretaker of the participants in the study. The data collectors were trained in ethical 
issues prior to the study.  
HIV testing followed the Ugandan national guidelines [154] which closely follow the WHO 
guidelines. Children over 18 months were tested using a rapid blood test with a sensitivity 
rate > 98%. To confirm positive results, a second test with a different antigenic specificity 
was used. If there was discordance between the 2 tests, an ELISA test (tie-breaker) was used 
to make a final diagnosis. For children under 18 months of age, a polymerase chain reaction 
(PCR) test was used to give a reliable HIV diagnosis. 
Children found to have symptoms of H. pylori and a positive antigen test, were offered a 
triple treatment of amoxicillin/claritromycin/omeprazole for 1 week free of charge. All 
participating children were offered a deworming treatment (if not treated in the last 6 
months) after providing the faecal sample. The treatment for the children in the hospital was 
not influenced by their participation in the survey.   
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4 Summary of results  
Paper I: “Helicobacter pylori in apparently healthy children aged 0-12 years in urban 
Kampala, Uganda: a community-based cross sectional survey” 
The overall prevalence of H. pylori in the 427 children was 44.3% (189/427). Early 
colonization was common, 28.7%, in children younger than 1 year of age. The age specific 
rates were 46.0% in children aged 1<3 years, 51.7% in children aged 3<6 years, 54.8% in 
children aged 6<9 years, and 40.0% in children aged 9<12 years (Figure 2, Paper I). There 
was a significant difference in prevalence by gender; female 38.5% versus male 49.8%, and 
by type of housing; permanent house 38.5% versus semi-permanent house 48.6%. 
Congestive living and education level of the female caretaker showed a clear trend for a 
difference in prevalence. Factors independently associated with H. pylori colonization 
included; drugs taken in last three months, using a pit latrine, sources of drinking water, and 
wealth index (Table 2, Paper I).  
The prevalence of H. pylori colonization among urban Ugandan children is high at an early 
age and increases with age. The impact of H. pylori colonization on children’s health in 
Uganda needs to be further clarified. 
Paper II: “Faecal calprotectin concentrations in apparently healthy children aged 0-
12 years in urban Kampala, Uganda: a community-based cross sectional survey” 
In the different age groups, the median faecal calprotectin concentrations were 249mg/kg in 
0<1 year (n=54), 75mg/kg in 1<4 years (n=89) and 28mg/kg in 4<12 years (n=159) (Figure 
2, Paper II). There was no significant difference in faecal calprotectin concentrations and 
education of the female caretaker, wealth index, gender, habits of using mosquito nets, 
being colonized with H. pylori or having other pathogens in the stool (Table 2, Paper II). 
Concentrations of faecal calprotectin among healthy children, living in urban Ugandan, a 
low- income country, are comparable to those in healthy children living in high-income 
countries. In children older than 4 years, the faecal calprotectin concentration is low. In 
healthy infants, faecal calprotectin is high. The suggested cut-off concentrations in the 
literature can be used in apparently healthy Ugandan children. This finding also shows that 
healthy children living under poor circumstances do not have constant inflammation in the 
gut. We see an opportunity to use this relatively inexpensive test for further understanding 
and investigations of gut inflammation in children living in low-income countries. 
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Paper III: “Prevalence of Helicobacter pylori in HIV-infected, HAART naïve Ugandan 
children: a hospital-based survey” 
236 children (121 female, 115 male) with a mean age of 2.9 ± 2.8 years were enrolled. The 
prevalence of H. pylori antigen was 22.5%. Age specific prevalence’s were; 1) for 0<1 year 
14.7%, 2) for 1<3 years 30.9%, 3) for 3<12 20.7% (Table 1, Paper III). Low CD4 cell 
percentage was significant associated with a lower prevalence of H. pylori; 12.5% versus 
30.4% (Table 2 Paper III). Having HIV WHO stage I (37.5% H. pylori colonization) versus 
WHO stage II-VI (20.8% H. pylori  colonization), was associated with a 2.3 fold higher 
prevalence of H. pylori (OR=2.3; 95% CI [0.9-5.6]. There was a trend for a difference in 
prevalence of H. pylori in children who had taken antibiotics for the last two weeks (21.6%) 
versus those who had not (35.7%). There was no significant difference in prevalence by 
gender, type of housing, congested living, education of female caretaker, drinking water 
sources or toilet facilities. 
HIV-infected, HAART naïve urban Ugandan children had a lower prevalence of H. pylori
colonization compared to healthy urban Ugandan children. Children with a low CD4 cell 
percentage and advanced clinical stage of HIV had an even lower risk of H. pylori
colonization. Treatment with antibiotics due to co-morbidity with infectious diseases is a 
likely explanation of the relatively low prevalence.  
Paper IV: “Faecal calprotectin concentrations in HIV-infected, HAART naïve 
Ugandan children: a hospital-based survey” 
The median faecal calprotectin concentrations in the 193 HIV-infected children, aged 0-12 
years in the hospital-based survey 208mg/kg (0<1 year), 171mg/kg (1< 4 years) and 
62mg/kg (4< 12 years) (Figure 2, Paper IV). There was a significantly lower faecal 
calprotectin concentration in the oldest age group. Thirty four of 59 (57.6%) children older 
than 4 years of age had faecal calprotectin above 50 mg/ml, and 25 of 59 (42.4%) had faecal 
calprotectin above 100mg/ml. Children with a high CD4 cell percentage had a significantly 
lower median faecal calprotectin than those with a low CD4 cell percentage. Children older 
than 4 years with diarrhoea at enrolment had a significantly higher faecal calprotectin 
concentration than those without diarrhoea. There were no significant differences between 
concentration of faecal calprotectin and WHO stage, fever on examination, colonized by H. 
pylori, education of the female caretaker, drinking water or child’s habit of using mosquito 
net. 
HIV-infected children older than 4 years had a higher median concentration of faecal 
calprotectin than apparently healthy children in the same geographical area. They had a 
higher average faecal calprotectin concentration than the recommended cut-of. Children 
with more advanced disease had higher faecal calprotectin concentrations regardless of age. 
More research is needed to see whether faecal calprotectin can be a marker for GI 
dysfunction in HIV-infected children. We hypothesise that a new tool for investigation of 
gut engagement in HIV-infected children is available. 
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5 Discussion 
5.1 Methodological issues 
The strengths and limitations of the two cross-sectional surveys building the foundation of 
this thesis and how they appear in the four papers are summarized in table 6. We have 
defined 3 main categories where strengths and limitations are potential; 1) Relating to 
precision, 2) Relating to internal validity, and 3) Relating to external validity. The details 
are discussed in-depth in the following.  
5.1.1 Study design 
The four papers in this thesis are based on two cross-sectional surveys; one population-
based and one hospital-based. A cross-sectional study gives information on a community at 
just one point in time, and is so suitable for measuring the prevalence of, but not the 
incidence of a disease. Another limitation of a cross-sectional study is that it cannot assess 
causal relationships, only associations. The outcome of a cross-sectional study depends on 
the sampling method used. The aim, of paper I and III, was to assess the prevalence of H. 
pylori in apparently healthy and HIV-infected children. We also wanted the healthy 
population to reflect the children coming to the hospital and therefore we chose to carry out 
the community-based survey in the neighbouring slum areas of the hospital. This selection 
should be representative of an urban low-income population of Kampala. The aim of paper 
II was to assess whether cut-off values for faecal calprotectin used in children in high-
income countries were also valid in children in low-income countries. As we found faecal 
calprotectin in apparently healthy children within the recommended cut-off value, we set 
out to explore whether it could be a useful method in HIV-infected children, paper IV. We 
used a cross-sectional design to perform the baseline study both in the apparently healthy 
children and the HIV-infected children since surveys are often used by finding baseline 
values.   
Both surveys were conducted in an urban area of the biggest city in Uganda. Some of the 
children in the hospital-based survey came from a more rural area after longer travelling, but 
most children were from urban Kampala. We do not have a rural population to compare 
with, which limited our findings in term of the generalization to the rural areas of the 
country and also rural areas in other sub-Saharan African countries. We have also studied 
only hospitalized HIV-infected children, which also limits the generalization to non-
hospitalized HIV-infected children.  
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Table 6. Methodological characteristics: Strengths and limitations of the studies 
Methodological 
characteristics 
Paper I Paper II Paper III Paper IV 
Relating to 
precision 
    
Sample size Adequate  Adequate Reduced Adequate  
Precision of the 
estimates of major 
findings 
High 
Narrow CI’s 
High 
Narrow CI’s 
High 
Narrow CI’s 
High 
Narrow CI’s 
Laboratory tests 
used a
-Sensitivity 
-Specificity 
-Accuracy
High 
High 
High 
High 
Low 
High 
High 
High 
High 
High 
Low 
High 
Feasibility of the 
tests a
Excellent Good Excellent Good 
Relating to 
internal validity 
    
Selection of the 
participants: 
-Inclusion 
-Refusals 
-“Drop-outs” 
-Potential for 
selection bias 
Consecutive door-
to-door 
Few 
Few 
Small 
Consecutive door-to-
door 
Few 
99 samples lost 
Small 
Consecutive admitted 
children  
Few 
Few 
Small 
Consecutive 
admitted children  
Few 
Few 
Small 
Potential for recall 
bias 
Limited Limited Limited Limited 
Efforts to reduce 
information bias 
Training and pilot 
prior to study, 
PI in field daily 
Training and pilot prior 
to study 
PI in field daily 
Regular data quality 
controls 
Regular data 
quality controls 
Efforts to reduce 
random error 
Daily data entry 
Double data entry 
Data cleaning 
Field editing by 
“Checks” b 
Use of statistics 
Daily data entry  
Double data entry 
Data cleaning 
Field editing by 
“Checks” b 
Use of statistics  
Early data entry  
Double data entry 
Data cleaning 
Field editing by 
“Checks” b 
Use of statistics  
Early data entry  
Double data entry 
Data cleaning 
Field editing by 
“Checks” b 
Use of statistics”  
Efforts to reduce 
Confounding 
Multiple logistic 
regression 
Children with diarrhoea 
and nose bleeding were 
excluded 
Multiple logistic 
regression 
Linear logistic 
regression 
Relating to 
external validity 
    
Study design Cross-sectional Cross-sectional Cross-sectional Cross-sectional 
Generalizability Urban children Urban children Urban children 
Hospitalized 
HAART naïve 
Urban children  
Hospitalized 
HAART naïve 
a H. pylori monoclonal antigen test and ELISA faecal calprotectin  
b “Checks” is explained in chapter 3.2.2 
FC  Faecal calprotectin 
PI Principal Investigator 
CI Confidence Interval 
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5.1.2. Limitations by comparing the results of the two surveys 
Two surveys were conducted in two different populations, apparently healthy children and 
HIV-infected children. Comparing the results of the two surveys have limitations, but the 
two studies also have similarities, making a comparison reasonable. Both study populations 
had children aged 0-12 years, similar gender distributions. The same antigen test and test for 
detection of faecal calprotectin was used, and both studies were performed in urban areas. 
Sanitation conditions did not differ much in the two populations. The limitations in 
comparing them were that one was a community-based with home visits and the other was a 
hospital-based. In the community-based study, 39% of the participants had taken antibiotics 
in the last 3 months versus 74% in the hospital-based study.  
5.1.3 The sample size 
A sample size calculation was done prior to both studies. Sample size calculations were 
based on reported prevalences of H. pylori in children and adults in other sub-Saharan 
countries. The spread of reported prevalences is large, table 2, and therefore we decided to 
use 50% prevalence for the sample size calculation, which maximises the sample size and 
minimises the risk of having a too small sample. In HIV-infected children, there are few 
reports on the prevalence of H. pylori, table 4, but according the literature a lower 
prevalence than in the apparently healthy children. Open-Epi data was used 
(http://www.openepi.com) to calculate the sample size needed in the apparently healthy 
children, assuming a 50% prevalence and using a 95% confidence interval. We calculated 
the sample size for the whole study population, but did not calculate the power needed for 
analysis of subgroups in advance of the studies. In paper I, we were able to enrol the sample 
calculated in advance. In the HIV-infected group, paper III, a 30% prevalence and a 95% 
confidence interval were assumed, we would have needed 323 children. The study was of 
236 HIV-infected children. If a prevalence of 22% had been assumed in advance, the 
sample size calculation would have given us a sample size of 264 children.  
For faecal calprotectin, no power calculation was done prior to the studies. We based our 
assumptions on the literature where no studies with higher participant numbers than those 
needed for H. pylori calculations were found. It was reasonable to use the median, instead of 
the mean, in paper II and IV because of the expected skewed distribution of faecal 
calprotectin.  
5.1.4 Validity 
The results of any research are only as trustworthy as the data upon which they are based. 
Data may be affected by the study participants, instruments used, people’s memories and 
biological variation. As a result, no epidemiological study will ever be perfect except to 
minimise errors as far as possible, and then assess the practical effects of any unavoidable 
error. The validity of an epidemiological study depends on the study design, the study 
conducted and data analysis. The validity of a test or an instrument is based on its ability to 
measure what it is intended to measure. The validity of a questionnaire is based on how 
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close the information collected is to the truth. Validity of a study can suffer due to bias. 
Validity of a study can be internal and external validity [155, 156].  
Internal validity 
Internal validity of a study says something about how it provides an unbiased estimate of 
what it claims to estimate. The usual threats to internal validity are ‘selection bias’, 
‘information bias’, confounding and chance, which needs to be kept to a minimum either 
through the study design or the data analysis. In the following paragraphs we will discuss 
the internal validity of the two surveys.  
Selection bias 
A selection bias is an error in selecting the study participants. Ideally, to assess the H. Pylori
prevalence in a population, all subjects in that population should be studied, but this is too 
time-and money-consuming.  
In paper I and II we did a consecutive enrolment in the study conducting door-to-door-
visits, omitting homes with no caretaker at home. This could potentially lead to a selection 
bias where we maybe have selected the poorest families being at home due to 
unemployment. In addition, we carried out data collection on Saturdays to try to minimise 
this. Daily assessment of non-participation revealed on average one to three homes out of 
~30 homes with no identifiable caretaker, i.e. less than 10%. We therefore consider the risk 
for an important selection bias to be small.  
In paper III and IV the enrolment was consecutive in the paediatric department; all children 
admitted who met the inclusion criteria were invited to participate in the study. Remarkably 
few refusals were reported, and therefore we consider our sample to be representative of 
children attending the hospital. For paper II, we lost 99 samples, and in paper IV, we lost 26 
samples in the transport. By comparing the subjects whose samples were lost with the main 
sample, by age, sex, socio-demographic factors and medical history, they do not differ 
essentially from those where faecal calprotectin was analysed. If we had used all the 
samples, the 95% confidence interval calculated in both papers would have been narrower. 
In paper IV, if more accurate data on faecal calprotectin had been available, maybe a 
connection to the WHO staging could have been found, and maybe the difficult explainable 
sex-difference would have been eradicated. We consider our findings of higher faecal 
calprotectin in children with more advanced disease, are valid as we had a large sample size 
(193).  
Information bias 
An information bias, also referred to as a measurement bias, have several aspects; 1 
instrumental errors, 2 underlying variability, 3 respondent errors, 4 observer errors and 5 
data-processing errors. Effort must be made to reduce the information bias in a study; high 
degrees of information bias reduce its precision.  
Ad 1 and 2: The faecal monoclonal antigen test we used for detecting H. pylori in paper I 
and III, has a high sensitivity, specificity, and accuracy in children, 91-96, 95-96  and 94-
96%, respectively [76, 77]. The test is very easy to use and read. A standard positive control 
test was performed after every 20 tests, all being verified as positive. The test used for 
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detecting the levels of faecal calprotectin in paper II and IV, is widely used in the clinic, and 
a good reproducibility was shown by our group in paper II. The technician who helped in 
performing the test did this as a part of her routine work. We found support in the literature 
that faeces could be frozen before testing [157].  
The questionnaires used were not influencing the prevalence of H. pylori or the levels of 
faecal calprotectin measured, but they may have been less precise in assessing socio-
economic status. We tried to minimize this error by creating a wealth index using principle 
component analysis (PCA). We combined 12-15 different assets in the households for the 
PCA.  
Ad 3: We asked questions that required recall: “Has the child had diarrhoea at any time 
within the last two weeks?” or “Has the child taken any antibiotics within the last three 
months?” These questions were followed up by linked questions such as “Has your child 
seen a doctor in the last two weeks/three months?” The data collectors cross-checked the 
answers if there were inconsistencies in the answers. They tried to achieve consistency 
without telling the responders what they were seeking. Some questions were prone to 
eliciting socially desirable answers, for instance the question “Is your child using a 
mosquito net regularly?”. The fact that only 33% responded “yes” to this question shows 
that social desirability did not gravely bias our studies. For other questions like the status of 
the sanitation facilities, we requested the data collectors to check these.  
Ad 4: To minimize the observer errors, we had a one-week training session prior to the 
study about the healthy children, and we had a two-day pilot training which was evaluated 
in advance of the study. Errors that occurred were corrected in the study. To minimize the 
observer errors concerning the HIV-infected children, E. Hestvik went trough the 
questionnaires regularly and discussed this with G. Ndeezi, who again had discussions with 
the data collectors.  
Ad 5: To reduce the errors in the data processing, we used logical coding such as “0” for No 
and “1” for Yes. Data was entered twice, once from the data collector, and once from E. 
Hestvik which were validated. We used “check” module for the data entering. Even if effort 
was made to minimize the measurement errors, it is unlikely that all errors were identified.  
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Confounding 
Confounding is a variable that might influence the results without being the component 
measured. Typical confounders are age, sex and factors linked to each other. Confounding 
can be understood as a triangle:  
Figure 8. Confounding in a cross-sectional survey 
We have tried to control for confounding by using multiple logistic regression and 
adjustments for several factors (shown in table 2 in paper I and table 2 in paper III). After 
adjustment in the apparently healthy children, we still found a higher prevalence of H. 
pylori in older children. In paper III, we still found a lower prevalence in those with more 
advanced disease. The unadjusted and adjusted ORs are not significantly different from 
each other. In paper II, we did not control for confounding by statistical analysis, but all 
children with nose bleeding or diarrhoea within last two weeks before enrolment were 
excluded from the analysis. We do not consider that any important confounding factors are 
attributable in this paper. In paper IV, we controlled in all children and in the subgroup of 
children older than 4 years whether diarrhoea at enrolment was not a factor on its own but a 
confounder for a low CD4 cell percentage (data not shown). From linear regression analysis 
there was no significant change in the median faecal calprotectin with 95% CI after 
adjusting for diarrhoea. We also adjusted for all factors shown in table 3 in paper IV by 
linear regression (data not shown), but there were no significant changes in median faecal 
calprotectin with 95% CI.  
Chance 
If the results presented in this thesis are not explained by the abovementioned factors, can 
they be the result of chance? In order to assess this, all results are reported with statistical 
indicators of the possibility of chance, mainly the 95% confidence intervals. With the rather 
high numbers of children studied, our confidence intervals are narrow, which means it is 
unlikely that the results are due to chance.   
External validity 
Can the results be generalised to a larger population than the one we have studied? The 
results from paper I and II are found in apparently healthy children, living under slum-like 
conditions with overall poor sanitation conditions in urban areas. We have to be careful 
using results generalized to other parts of Uganda or East-Africa, where living conditions 
may be quite different. In paper III and IV the children were hospitalized and probably 
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sicker than the average HIV-infected child. They had probably received more treatment for 
opportunistic infections compared to the average HIV-infected child, several were in 
clinical WHO stage IV. Today the paediatric HAART treatment is being scaled up in 
Uganda and other sub-Saharan countries, and we will need to conduct other studies to assess 
the effect of this implementation on the prevalence of H. pylori. The effect on the GI tract 
has to be evaluated in the light of increased accessibility to HAART.  
In paper I, we have found an overall prevalence of H. pylori of 44.3%, increasing with age, 
associated with poor living standard and male gender. Our findings are supported by the 
literature, but it is expected that the exact prevalence will show variations from place to 
place. In paper III, we have shown that the prevalence of H. pylori in HIV-infected children 
is about half than in apparently healthy children. Several studies have highlighted the low 
prevalence of H. pylori in their findings. Our study adds to a growing body of evidence that 
HIV-infected children are less frequently infected with H. pylori.   
Surprisingly few studies have focused on faecal calprotectin in populations in low-income 
countries, only one report being found [158]. More research is needed before any of the 
results in those two papers can be generalized.  
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5.2 Discussion of the findings 
5.2.1 Prevalence of Helicobacter pylori  
The prevalence of H. pylori has been studied extensively since its discovery in 1983 [46], 
and many surveys have been conducted in low-, middle- and high-income countries. 
Comparing studies, however, is not easy as the study settings, the diagnostic methods, age 
of participants and the criteria for inclusion and exclusion differ. Very few studies have 
been carried out focusing on children, particularly apparently healthy children and no 
studies have looked at urban children specifically. In HIV-infected children, living in high 
endemic regions both for HIV and H. pylori, no larger studies have been conducted. 
Commonly, there is a mix of participants with and without different HAART regimes [101]. 
Many studies are conducted in countries with a low prevalence of HIV and good treatment 
options for HIV [102, 103]. One sub-Saharan study was performed with children reporting 
to have gastrointestinal complications [101]. As far as we know, no prevalence studies of H. 
pylori in Ugandan children had been carried out before our surveys.  
We found an overall prevalence of 44.3% in the apparently healthy population, with an 
increasing prevalence with age. In the HIV-infected children, the prevalence was 22.5% 
with the highest prevalence among children aged 1-3 years. A comparison of the 
prevalences in the surveys is shown in Figure 2, Paper III. The prevalence found in 
apparently healthy children compares well with the range of prevalences reported from 
other sub-Saharan African countries [15, 16, 84-86, 88, 107-109].  
In HIV-infected children, the literature is much more limited, and a comparison is more 
complicated. To the best of our knowledge, only three papers have reported the prevalence 
of H. pylori in HIV-infected children [101-103], and none in exclusively HAART naïve 
children. Despite the difference found in prevalence rates of H. pylori among HIV-infected 
children and adults, many studies point to a lower prevalence in the HIV-infected 
population compared to non-HIV-infected populations, but the findings are not universal. 
The controversies are well documented in table 1 in the review by Romanelli et al. 2007 
[104]. Our survey is one of the largest studies carried out in an HIV-infected population. In 
contrast, almost all studies show that the prevalence of H. pylori in HIV-infected children is 
lower, especially in areas with a high prevalence of HIV and H. pylori. We found that H. 
pylori colonization was significantly higher in children aged 1-3 years compared to children 
younger than 1 year of age. This is comparable to data from apparently healthy children 
from the same region [159], but it has not been described previously among HIV-infected 
children in this age group. In our survey, the prevalences in all age groups are lower than 
those in apparently healthy children. We speculate that the colonization rates among the 
HIV-infected are the same as in apparently healthy children, but the use of antibiotics in the 
HIV-infected children is high, which is enough to decrease the prevalence. Seventy-four 
percent of the children had taken antibiotics within the last 3 months and 95% of the survey 
participants were on antibiotics at enrolment or had taken antibiotics within the preceding 
two weeks, which might explain the lower colonization rates. The use of antibiotics against 
opportunistic infections in HIV-infected populations is the most hypothesised explanation 
for lower colonization rates [104, 160, 161]. The difference between HIV-infected children 
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not treated or treated with antibiotics is not significant mainly due to the low numbers of 
untreated subjects.  
5.2.2 Factors associated with Helicobacter pylori colonization 
Several studies have shown a high prevalence of H. pylori among people in low-income 
countries [16, 84-86]. Well recognized risk factors include crowded living conditions in 
childhood, a large number of siblings and unclean water [86, 162]. A meta-analysis of 10 
studies conducted over the last 20 years [163] failed to find a difference in prevalence of H. 
pylori according to gender. In apparently healthy children in our survey, the factors found to 
be significantly associated with H. pylori colonization were male gender and semi-
permanent housing. Those living in semi-permanent housing might represent a lower socio-
economic status than those living in permanent houses (table 2 Paper I). Congested living 
with more than 4 people in the household was associated with an increase in H. pylori 
prevalence, but it was not significant. We did not found that the prevalence of H. pylori 
colonization was increased with decreasing socio-economic status of the family as found in 
other studies from the same region [16, 86, 164]. A possible explanation is the small socio-
economic differences in our study population; the study was conducted in one parish only 
and within an area characterized by informal settlements, congested living, lack of proper 
sanitation conditions, low education level among adults and small variation in income per 
family. Almost 90% of the participants in our survey got drinking water from a public tap; 
Plan International® has provided the parish with tap water at subsidized prices.  
In HIV-infected populations, it has been shown that the prevalence of H. pylori is lower 
when CD4 cell count is low [101, 105]. In a study from Argentina of adults [105], the 
authors conclude that HIV-infected patients with H. pylori had a higher mean CD4 cell 
count than those without H. pylori, and a Zambian study also of adults [106] showed that 
HIV-infected adult patients with CD4 cell counts below 200cells/mm3 were less likely to 
have positive H. pylori serology.  Unfortunately, none of these studies have reported a CD4 
cell count in percentage in children. We identified a statistically significantly lower 
colonization rate of H. pylori in HIV-infected children who had a low CD4 cell percentage 
(table 2 Paper III). In the HIV-infected children, we could not find the same associations as 
found in the non-HIV-infected children. There was no significant difference in prevalence 
by sex, type of housing, congested living, education of female caretaker, drinking water 
sources, toilet facilities, reported abdominal pain or wealth index. A possible explanation 
for the lack of such association, as described in the non-HIV-infected children [16, 86, 159, 
164], is that the impact of the CD4 cell percentage is strong and is independent of the above 
mentioned factors. 
5.2.3 Concentrations of faecal calprotectin  
Calprotectin was discovered in 1979 and soon came into use to distinguish IBD from other 
GI disorders. With time, other conditions causing elevated levels of faecal calprotectin were 
found. Prior to this thesis, all research on calprotectin was conducted in high-income 
countries. The prevalence of diseases in the GI tract in high-income countries is different 
compared with sub-Saharan Africa with lack of studies on prevalence of for instance IBD 
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and celiac disease, but with a high burden of infectious diseases in the GI tract. In 2000, a 
new method for detecting faecal calprotectin was established [157] that was more accurate, 
easier to perform and required smaller amounts of faeces. Normal values for faecal 
calprotectin have been established in children and adults, table 7. The upper cut-off point is 
still under debate, which upper limits provide the best sensitivity and accuracy? Several 
studies have also looked at levels of faecal calprotectin, by upper and lower GI infections, 
but most of these studies had a limited number of infections, different stages of infections or 
GI infections have been seen as one without closer information about the type of infection.  
No conclusions on concentrations in different infections can be drawn from the existing 
literature.  
Table 7. Faecal calprotectin concentrations in apparently healthy children and adults 
Author Age Number of 
 participants 
Assay Median FC 
(mg/kg) 
95% CI 
Fagerberg [125] 4-17 years 117 New 13.6 9.9-19.5 
Olafsdottir [126] 1-13 years 24 New 40a 28 b
Berni Canani 
[146] 
1-18 years 76 New 28 3-95.3 c
Bremner [145] 5-14 years 7 New <15.6 <15.6-39 d
Nissen [165] 1-15 years 21 New 17 7-41 d
Carroccio [166] 1-10 years 10 New 15 10-40 
Bunn [137] 1.5-15.3 years 31 Old 10.5 e 2.5-31.5 e
Carroccio [166] adults 10 New 20 10-40 
Tøn [157] adults 59 New 26 20-36 
Tibble [167] adults 96 Old 11.5 e 8-25 e
Røseth [140] adults 53 Old 15 e 35 e, f
Hestvik [168] 0-1 year 54 New 249 180-403 
 1-4 years 89 New 75 53-119 
 4-12 years 159 New 28 25-35 
a mean value 
b   standard deviation 
c   5th and 95th percentile 
d   range 
e   original data in mg/L, multiplied with factor 5 to get mg/kg [157] 
f   Røseth choose 10mg/l as the upper limit, no lower limit reported 
[ ]  reference number  
CI confidence interval 
FC  faecal calprotectin 
In our survey on apparently healthy children, all those who reported having had diarrhoea or 
had had nasal bleeding within the last two weeks before the study, were excluded, but we 
did not exclude those with detected GI infections. The median faecal calprotectin 
concentration in children older than 4 years of age was 28mg/kg, and within the cut-off 
level suggested for that test. Based on this, we concluded that cut-off limits used in children 
living in high-income countries could be used in children, and most likely also in adults in 
low-income countries. Those children were healthy, but they were colonized with more 
pathogens than children in high-income countries. Studies have shown that adults with 
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Giardia intestinalis have comparable levels [169]. Colonization with H. pylori can cause 
changes in the gastric mucosa [170], but upper-GI disorders have shown little increase in 
faecal calprotectin levels [171]. A study from Uganda on children and adults infected with 
Schistosomiasis, could not find increased levels of faecal calprotectin in those infected 
compared to those not infected [158]. By identifying elevated levels of faecal calprotectin in 
children living in low-income countries, the follow-up might have to be different from that 
in children living in high-income countries due to the known differences in the underlying 
causes of GI disorders. Initially, GI pathogens have to be eliminated as the cause of the 
increased concentrations, and only thereafter more rare conditions causing increased GI 
permeability like IBD, celiac disease and cancer should be searched for.  
To the best of our knowledge, our study of the concentrations of faecal calprotectin in an 
HIV-infected, HAART naïve population is the first to be conducted in children. Only one 
study in Italian adults has been published before, and they found that faecal calprotectin was 
higher than 50 mg/ml in 27 of 53 HIV-infected, HAART naïve adult patients [41]. This is 
comparable to our findings in children, 34 of 59 had levels higher than 50mg/ml. In the 
study children, we did not exclude those with diarrhoea, and nasal bleeding was not reported 
in any of the children. The two populations had different exclusion criteria and a direct 
comparison is difficult, but in spite of this we found more than two-fold increase in the 
median faecal calprotectin concentration in children older than 4 years of age, 62mg/kg and 
a median concentration over the recommended cut-off level for the test. We do know that 
persons presenting with advanced HIV disease have involvement of the GI tract in their 
diseases: it is reasonable that the faecal calprotectin increased with more advanced disease. 
This is an indicator for an ongoing inflammation of the gut in the HIV-infected children. 
They have an impaired gut mucosa with increased permeability, which again can lead to 
loss of micronutrients, proteins and a damaged gut/blood barrier and an increased chance of 
bacteraemia.  
5.2.4 Concentrations of faecal calprotectin in children younger than 4 years of 
age 
In children younger than 4 years of age, there are no established reference values. Several 
studies have shown that the concentrations decrease with age [126, 127] which agree with 
our decrease (table 1, Paper II). The concentrations found in the apparently healthy children 
are comparable to those reported elsewhere [126, 165]. In the HIV-infected children, the 
concentrations in the youngest children were high and comparable with those in non-HIV-
infected children. This might be explained by a naturally high permeability of the gut in 
healthy infants. In the HIV-infected toddlers, aged 1-4 years, the median faecal calprotectin 
was 2.3 fold higher than in the apparently healthy children, and in the HIV-infected 
children, aged 4-12 years a 2.5 fold increased levels was found compared to non-infected 
children. In healthy toddlers, the permeability of the gut is decreasing and the levels of 
faecal concentration are decreasing, but in HIV-infected children, the gut is repeatedly 
exposed to different pathogens, repeatedly treated with antibiotics due to opportunistic 
infection, and some might have developed an HIV enteropathy. Those factors could explain 
the elevated levels of faecal calprotectin in this age group. A comparison of all age groups 
of non-HIV and HIV-infected children is shown in figure 9. 
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Figure 9. Faecal calprotectin in apparently healthy and HIV-infected children by age
5.2.5 Factors associated with increased concentrations of faecal calprotectin  
Increased concentrations of faecal calprotectin are caused by an increase of neutrophils in 
the gut and the two main factors shown are increased gut permeability and bleeding into the 
GI-tract. Gut inflammation will lead to increased permeability. It is estimated that a blood 
loss of about 100ml/day would be required to bring the level above the upper reference limit 
[140]. In our surveys, we have excluded those with nose bleeding, which can cause a blood 
loss of 100ml/day or more. None of the girls included had started having menstrual 
bleeding. Røseth [140] argued that GI haemorrhage due to GI cancer is an unlikely source 
of increased faecal calprotectin. The increase of faecal calprotectin in our HIV-infected 
populations is most likely due to gut inflammation and increased permeability. In paper II, 
we have shown that two common pathogens, H. pylori and Giardia intestinalis, were not 
causing increased levels of faecal calprotectin. An Ugandan study of children and adults 
with Schistosomiasis, increased levels of faecal calprotectin were not found [172]. Only 
8.2% of the children in the apparently healthy population had other pathogens than H. pylori
and Giardia intestinalis found by microscopy or faecal culture; and even those infected had 
a median faecal calprotectin below the recommended cut-off value. We have also shown 
that faecal calprotectin levels are independent of education of the female caretaker, health 
behaviour and wealth index. In the apparently healthy population, we did not check for 
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viruses or crypto-and microsporidia infections. But if infected, as long as they were 
asymptomatic, they were unlikely to have an increased permeability of their gut.  
In the HIV-infected children, faecal calprotectin was detectable in all children regardless of 
age, clinical staging of HIV and CD4 cell percentage. This shows that immunosuppressed 
people are capable of producing calprotectin and that they have variability in their 
concentrations of faecal calprotectin similar to immunocompetent subjects. We therefore 
conclude that faecal calprotectin can be used in HIV-infected persons. HIV-infected 
children with ongoing diarrhoea had significantly higher levels of faecal calprotectin than 
those without diarrhoea. The higher median concentration of faecal calprotectin in those 
with ongoing diarrhoea can be explained by increased gut permeability caused by 
pathogens, but also by HIV enteropathy [23]. Only in three children older than 4 years of 
age were pathogens others than H. pylori detected, one with E.coli, one with hook worm 
and one with Giardia intestinalis.  
In our survey of HIV-infected children the faecal calprotectin concentrations increased as 
the CD4 cell percentage decreased (table 2 Paper IV). This is reflecting that children with 
more advanced disease have increased inflammation of the gut. This shows that faecal 
calprotectin is a useful marker in an HIV-infected population. Faecal calprotectin is mainly 
found in the neutrophils and is not influenced by the decrease in lymphocytes seen in HIV-
infected persons. More research is needed to determine whether faecal calprotectin can be a 
marker for GI dysfunction in HIV-infected children. We hypothesise that we have a new 
tool for investigation of gut engagement in HIV-infected children.  
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6 Research challenges 
H. pylori is classified as a group I carcinogen [51], and is associated with a 1-2% lifetime 
risk of gastric cancer [55]. At Mulago Hospital where our second survey took place and 
where many of the children encountered in the first survey sought medical advice, there was 
no established method for detecting of H. pylori colonization. Gastroscopy was not 
available on a regular basis. Gastric cancer in adults frequently went undiagnosed.  
In the joint European and North-American guideline [81], the recommendation is not to test 
asymptomatic children for H. pylori. Testing for H. pylori in asymptomatic children can be 
considered if a first degree relative has gastric cancer or in children with refractory iron 
deficiency anaemia. To treat H. pylori infections is only recommended if a child has clinical 
symptoms or if a gastric ulcer is detected by gastroscopy with or without a positive test of 
H. pylori. Several studies of children have indicated that H. pylori can play a role in growth 
failure [15, 173] and iron deficiency [174], and both these problems are common in 
Ugandan children [175, 176]. Due to the known high prevalence of H. pylori in Uganda and 
sub-Saharan Africa, diagnostic tools for detection need to be considered, and more research 
on treatment strategies according to resistance problems should be initiated. Guidelines for 
management of H. pylori infection in endemic low-income countries are urgently required.  
Faecal calprotectin is a “new tool” in gastroenterology in Uganda. We know that many 
children suffer from acute and persistent diarrhoea in Uganda. For those suffering from 
acute diarrhoea, fluid treatment is necessary, and good guidelines are available. For those 
with persistent diarrhoea, all types of pathogens must be detected and eventually treated. 
Here we have found a lack of good guidelines for work-up and treatment. In many cases, 
there will be no identifiable pathogen causing the diarrhoea. They may suffer from other 
conditions like IBD, celiac disease, food allergy/intolerance, etc. Due to the lack of 
opportunities to perform gastroscopy, faecal calprotectin might here be a tool to distinguish 
between different conditions, helping to choose a treatment strategy and follow up treatment 
response. The burden of disease of persistent diarrhoea is remarkable. Effort must be made 
to find good methods to monitor and treat the condition; faecal calprotectin can be a tool to 
follow up the degree of gut inflammation in children. In several medical centres in Uganda, 
the equipment needed to perform ELISA is available, and due to the quality of faecal 
calprotectin being stable at ambient temperature for a longer time, faeces can be sent by 
regular mail to centres for testing. The role of faecal calprotectin in HIV-infected children 
needs more research, but our findings show that faecal calprotectin is a tool to be used in the 
diagnosis and follow up of HIV-infected children. Can repeated individual faecal 
calprotectin measurements be used as a risk marker for developing GI failure in HIV-
infected children and adults?  
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7 Conclusions 
The surveys presented in this thesis show that colonization with H. pylori is common, even 
in apparently healthy young children in Uganda (44.3%). It is increasing with age and is 
associated with poor socio-economic status and boys are more at risk than girls (Paper I).  
HIV-infected children had a lower prevalence of H. pylori (22.5%) than apparently healthy 
children in the same geographical area. Children with more advanced disease had a lower 
prevalence; this might be due to frequent use of antibiotics for opportunistic infections 
(Paper II). In other studies, it is suggested that H. pylori causes growth failure and 
micronutrient deficiencies, but no such studies have been carried out in Uganda. The impact 
of H. pylori on children’s health in Uganda [177] needs to be further clarified. 
Cut-off limits for faecal calprotectin, suggested used in children living in high-income 
countries, can also be used in Ugandan children (Paper III). We have shown that pathogens 
inhabiting the upper gastrointestinal tract have limited influence on the faecal calprotectin. 
There is an opportunity to use this relatively inexpensive test for further understanding and 
investigations of gut inflammation in children living in low-income countries.  
Faecal calprotectin can be measured in HIV-infected children, and we suggest that it can be 
used as a tool for evaluating gut inflammation. In our survey, we found it to be higher in 
those with more advanced disease (Paper IV). The diagnostic value of faecal calprotectin in 
HIV-infected children, and its use in follow up the gut function in those infected children, 
need to be further clarified.  
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